The biosimilars reach the US market as the US insulin space has seen seismic changes in the last few years, with a clamour of ...

During a hearing, representatives for the Newsom administration said they could not provide a timeline for when ...

For Novo Nordisk, a company still rooted in principles ... Its new fast-acting insulin Fiasp was also recently approved in Europe, but has faced delays in the US because of FDA safety questions.

While the issue has fallen from the headlines after several moves to cap the cost, some patients with diabetes still often ...

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...

Novo Nordisk accounts for 34% of the global ... Novo's newer insulin therapies like Tresiba (2029) and Fiasp (2030). We expect further insulin improvements--like Novo's weekly insulin Awiqli ...

Novo Nordisk A/S NVO reported fourth-quarter 2024 ... In Diabetes Care, fast-acting insulin Fiasp’s revenues were down 45%. NovoRapid revenues increased 62% and Human insulin revenues increased ...